07:00 , Jul 16, 2007 |  BioCentury  |  Product Development

Wounds: Not open & shut

The failure of a series of wound healing agents, combined with disappointing sales for the few products that were approved, eroded interest in the space in the 1990s. But efforts now have been rekindled by...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In a mouse model of diabetic ulcers, a once-daily oral dose of iroxanadine significantly increased median wound closure time. Wounds in treated animals closed in 14 days vs. 23.5 days in untreated mice (p<0.0001). Iroxanadine...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Clinical News

Arimoclomol regulatory update

FDA granted Fast Track designation to arimoclomol to treat amyotrophic lateral sclerosis (ALS). Arimoclomol, which has U.S. Orphan Drug designation, is in Phase IIa for the indication. CYTR acquired the hydroxylamine derivative that induces heat...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Clinical News

Arimoclomol: Phase II delayed

CYTR said FDA will require certain clinical tests be added to the protocol for a U.S. Phase II trial of arimoclomol to treat ALS in order to lift the clinical hold on the study. The...
07:00 , May 9, 2005 |  BC Week In Review  |  Clinical News

Arimoclomol regulatory update

FDA granted Orphan Drug designation to arimoclomol to treat amyotrophic lateral sclerosis (ALS). The hydroxylamine derivative was acquired from Biorex Research and Development Co. (Veszprem-Szabadsagpuszta, Hungary) (see BioCentury, Oct. 11, 2004). CYTP plans to submit...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In a rat model, arimoclomol lowered the amount of fat in the serum of the animal and inhibited the accumulation of fat in the liver and muscle tissue after they were fed a high fat...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In a rat model of diabetes, arimoclomol significantly improved the ability to remove glucose from the bloodstream after consuming large amounts of glucose. The hydroxylamine derivative was acquired from Biorex Research and Development Co. (Veszprém-Szabadságpuszta,...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In a rat model with high blood pressure and damaged hind limb capillaries, iroxanadine significantly improved the flow of blood to the tissues of legs by protecting endothelial cells from damage. The small molecule that...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In a pig model, iroxanadine treatment following balloon angioplasty significantly reduced coronary restenosis compared to the animals that did not receive any further drug treatment. The small molecule that activates chaperone proteins to repair or...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

CytRx preclinical data

In rat models of diabetes either genetically predisposed to Type II diabetes or by inhibiting insulin production, arimoclomol significantly inhibited the production of glucose in the liver. The hydroxylamine derivative was acquired from Biorex Research...